Bo Cumbo, President and CEO of Solid, commented: “With three clinical-stage programs for neuromuscular and cardiac diseases, Solid now stands at the forefront of innovation in genetic medicine. The strategic expansion of our pipeline beyond Duchenne to include differentiated therapies for both FA and CPVT marks a meaningful stride forward that reflects both our disciplined execution and steadfast dedication to the patient communities we serve.”
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLDB:
- Solid Biosciences reports inducement grants under Nasdaq listing rule
- Solid Biosciences receives FTD from FDA for SGT-501
- Vor Bio appoints Cumbo, Detheux to board of directors
- 3 Best Stocks to Buy Now, 7/14/2025, According to Top Analysts
- Solid Biosciences’ Promising Advancements in Cardiac Gene Therapy: A Buy Recommendation